Joined July 2015
- Tweets 229
- Following 70
- Followers 244
- Likes 11
219 Photos and videos
30 Oct 2025
Exciting progress!
NLS Pharmaceutics & Aexon Labs expand the #DOXA platform with the #AEX6xx series — targeting cognition, arousal, & neuroprotection. A strong step toward next-gen #CNS innovation
finance.yahoo.com/news/nls-p…
78
29 Oct 2025
The BIRD Foundation will continue supporting ITOL-102, our joint Diabetes program with @iToleranceBio — now part of NewCelX Ltd. @KadimastemLTD
#NLSPharma #BIRDFoundation #NewCelX #CellTherapy #diabeteschat
finance.yahoo.com/news/nls-p…
49
23 Oct 2025
It’s official! ✅ @Nasdaq has approved our merger with @KadimastemLTD .
Closing expected Oct 30, 2025 — forming NewCelX (Nasdaq: NCEL), a global biotech innovator advancing cell & CNS therapies.
#NLSPharmaceutics #Kadimastem #NewCelX #Nasdaq #biotech
finance.yahoo.com/news/nls-k…
67
30 Sep 2025
NLS shareholders approved the merger with @KadimastemLTDâś…
Huge milestone cleared before forming NewCelX Ltd. (Nasdaq: NCEL) → a diversified biotech uniting cell therapy & CNS expertise.
finance.yahoo.com/news/nls-p…
1
106
10 Sep 2025
Exciting news! 🎉 The @SECGov has declared effective our Form F-4 for the planned merger with @Kadimastem.
The combined company, NewCelX, will unite cell therapy & small-molecule innovation to tackle #ALS, #Diabetes, & #CNS disorders.
finance.yahoo.com/news/kadim…
3
5
416
4 Sep 2025
🚨 Patent milestone: Our merger partner @KadimastemLTD secures IP protection in Hong Kong for its IsletRx #diabetes program—expanding global coverage after Europe, U.S. & India. Hong Kong = key Asia hub gateway to China. finance.yahoo.com/news/nls-p…
152
17 Jul 2025
Big news! BIRD Foundation greenlights more funding for iTOL-102, our merger partner's diabetes cure-in-progress with @KadimastemLTD & @iTolerance_inc . Plus: our CSO Dr. Eric Konofal is shortlisted for the 2025 Prix Galien for his groundbreaking work in narcolepsy! 🧠💉
1
1
2
259
30 Jun 2025
We’ve closed the final $1M of our $3M financing! This supports our merger with Kadimastem and advances programs in ALS and diabetes. @KadimastemLTD #biotech #regenerativemedicine
finance.yahoo.com/news/nls-p…
1
2
3
414
16 Jun 2025
CEO Issues Letter to shareholders: NLS has raised $6M , cleared all debt, and advanced key clinical programs. The Kadimastem merger is on track as we prepare for ALS and diabetes trials.
🧾 finance.yahoo.com/news/nls-p…
#Biotech #ALS #Diabetes #CNS
3
5
317
21 May 2025
At @ASCPorg NLS Pharmaceutics will present preclinical results showing Mazindol ER reduces both fentanyl reward and withdrawal symptoms in animal models.
A promising non-opioid approach to fighting addiction.
đź“ŤPoster #KO-943 | May 29
#CNS #PharmaNews #OpioidCrisis
ALT https://finance.yahoo.com/news/nls-pharmaceutics-present-data-dual-113000452.html?guccounter=1
3
5
391
15 Apr 2025
Exciting news! NLS' KO-943 study shows Mazindol reduces fentanyl-induced reward in animal models! As we prepare for our merger with @KadimastemLTD, Mazindol remains a key focus for future strategic partnerships in addiction treatment. #AddictionResearch #addiction #biotech
ALT https://finance.yahoo.com/news/nls-pharmaceutics-announces-positive-results-130000361.html
3
4
229
31 Mar 2025
NLS has announced the closing of up to $2M equity financing and a $25M equity facility agreement! These financial resources will support our merger with @KadimastemLTD and the advancement of clinical trials for transformative therapies in ALS and diabetes. Exciting times ahead!
ALT https://finance.yahoo.com/news/nls-pharmaceutics-kadimastem-announces-3-131000698.html
1
1
4
213
27 Feb 2025
NLS Pharmaceutics announces new preclinical data for AEX-2, our groundbreaking dual orexin receptor agonist! 🧠✨ AEX-2 enhances wakefulness & reduces cataplexy—transforming sleep disorder treatments! #innovationquotes feeds.issuerdirect.com/news-…
2
4
153
25 Feb 2025
👏 Kudos to @KadimastemLTD and @iTolerance_inc ! They completed a pre-IND meeting with the @US_FDA, bringing us closer to a potential cure for Type 1 Diabetes. Exciting times ahead for our future combined company!nasdaq.com/press-release/kad…
1
2
147
15 Oct 2024
Big news from NLS Pharmaceutics! We raised $3.2M in a private placement and settled $4M in debt. Plus, we believe we’ve regained Nasdaq compliance!
Full article: rb.gy/8qqfjr
#nlspharmaceutics #narcolepsy $NLSP
2
1
321
25 Sep 2024
NLS Pharmaceutics (Nasdaq: NLSP) announces 1-for-40 reverse share split effective Sept 27, 2024. Shares will trade under the same symbol “NLSP” but with a new CUSIP.
Full article: rb.gy/mgkk8e
#nlspharmaceutics #narcolepsy $NLSP
2
285
30 Jul 2024
NLS Pharmaceutics (NASDAQ: NLSP) and Kadimastem (KDST.TA) are merging!
Kadimastem shareholders to hold 85%
New entity to trade on Nasdaq as Kadimastem
NLS’s DOXA platform continues
Read the full article here: rb.gy/wnw14a
#nlspharmaceutics $NLSP
1
2
245